諾輝健康(6606.HK)跳漲近15% 旗下幽幽管獲批國家藥監局幽門螺桿菌消費者自測第一證
格隆匯1月7日丨諾輝健康(6606.HK)跳空高開14.75%報22.1港元,最新市值95億港元。公司昨晚宣佈,旗下幽門螺桿菌檢測產品幽幽管獲得國家藥品監督管理局(NMPA)批准的三類醫療器械註冊申請。這是國家藥監局批准的中國首個適用於“消費者自測”的幽門螺桿菌檢測產品。近日,在美國衞生與公眾服務部(HHS)發佈的第15份致癌物報吿中,幽門螺桿菌導致的慢性感染被列為明確人類致癌物。昨日A股相關概念股集體上漲。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.